Uzbekinvest Acquires Risk and Capital Modelling Capabilities From Ultimate Risk Solutions Which Helped Them Attain Stable AM Best Rating
Ultimate Risk Solutions (“URS”) is proud to announce its important contribution into assisting Uzbekinvest Export-Import Insurance Company of Uzbekistan (“Uzbekinvest”) in attaining their stable AM Best credit rating. Through the development of advanced risk models of Uzbekinvest’s insurance and reinsurance lines of business, including catastrophe risk, URS has contributed significantly to this achievement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240730430996/en/
Uzbekinvest acquires risk and capital modelling capabilities from Ultimate Risk Solutions (URS) which helped them attain stable AM Best rating (Graphic: Business Wire)
AM Best, a global credit rating agency specializing in the insurance industry, has revised the outlook for Uzbekinvest from negative to stable. The Financial Strength Rating remains at B (Fair), and the Long-Term Issuer Credit Rating at “bb” (Fair). This positive shift reflects Uzbekinvest’s enhanced risk-adjusted capitalization, in part attributed to the sophisticated risk modelling and probable maximum loss estimation facilitated by URS.
URS’s expertise in risk analysis and modelling has been instrumental in this process, showcasing the company’s commitment to delivering tailored risk solutions that enhance the financial stability and performance of its clients.
“Our company, which is the largest insurance and reinsurance provider in Uzbekistan, has made significant advances in the international markets, and is striving to become a global player closely working with AM Best during the process. Risk and capital modelling capabilities offered by URS technologies allow us to keep an eye on the solvency and stability of our global risk portfolio as it continues to grow,” said Rustam Azimov, General Director of Uzbekinvest.
“We are delighted to have supported Uzbekinvest in their journey towards improved financial strength and stability,” said Alex Bushel, Founder and CEO at Ultimate Risk Solutions. “Our team’s dedication to developing sophisticated and comprehensive risk models underscores our mission to empower our clients with the tools necessary for effective risk management and sustainable growth.”
This collaboration marks a significant milestone for both Uzbekinvest and URS, highlighting the importance of innovative risk management strategies in the insurance sector. As URS continues to pioneer in risk modelling and analysis, it remains committed to helping its clients navigate the complexities of risk with confidence and precision.
About Uzbekinvest:
Uzbekinvest Export-Import Insurance Company JSC is a prominent insurance and reinsurance provider in Uzbekistan and globally. The company is committed to offering reliable and comprehensive insurance and reinsurance solutions to its clients, backed by leading modern technologies and a team of dedicated professionals. This company manages total assets valued at USD 164 million and maintains substantial reserves amounting more than USD 106 million, indicating strong financial stability and capacity to cover potential liabilities. Uzbekinvest boasts a robust global footprint, handling risks from 132 countries. It maintains strong partnerships with major reinsurance companies such as Munich Re, Swiss Re, Allianz, Zurich Insurance Company and collaborates with top-tier broking firms including AON, Willis, Marsh, Guy Carpenter, Howden and others to enhance its market reach and service capabilities.
About Ultimate Risk Solutions:
Ultimate Risk Solutions (URS) is a leading provider of risk modelling and analysis technologies and services, offering advanced solutions for insurance companies and financial institutions globally. With a focus on innovation and precision, URS delivers technologies that help clients enhance their risk management practices and achieve their strategic objectives.
Link to AM Best press release regarding revised Uzbekinvest rating outlook:
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730430996/en/
Contacts
Sasha Kuznetsov, URS Marketing and Communications Lead | akuznetsov@ultirisk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom